1270301-63-7

Upstream product

• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 80126-50-7 (R)-2'-chlorophenylalanine 

Downstream Products

• 1415312-22-9 C₁₉H₂₁ClN₂O₄ 
• 1415310-29-0 2-{2-[(1R,2R)-1-(2-chlorobenzyl)-2-ethoxycarbonyl-2-hydroxyethylcarbamoyl]pyridin-4-yl}benzoic acid ethyl ester trifluoroacetic acid salt 
• 1415312-55-8 2-{2-[(1R,2R)-1-(2-chlorobenzyl)-2-ethoxycarbonyl-2-hydroxyethylcarbamoyl]pyridin-4-yl}benzoic acid t-butyl ester 
• 1415310-26-7 2-{2-[(1R,2R)-2-carboxy-1-(2-chlorobenzyl)-2-hydroxyethylcarbamoyl]pyridin-4-yl}benzoic acid trifluoroacetic acid salt 
• 1415312-56-9 (2R,3R)-3-[(4-bromo-pyridine-2-carbonyl)-amino]-4-(2-chloro-phenyl)-2-hydroxy-butyric acid ethyl ester 
• 1415512-66-1 5-[(1R,2R)-1-(2-chlorobenzyl)-2-ethoxycarbonyl-2-hydroxyethylcarbamoyl]-2H-pyrazole-3-carboxylic acid ethyl ester 
• 1415312-30-9 (2R,3R)-3-Amino-4-(2-chloro-phenyl)-2-hydroxy-butyric acid ethyl ester 
• 1415312-28-5 (2R,3R)-3-Amino-4-(2-chloro-phenyl)-2-hydroxy-butyric acid Methyl Ester 
• 1415481-83-2 (2R,3R)-4-(2-chlorophenyl)-2-hydroxy-3-[4-(3-methyl-5-oxo-4,5-dihydro-pyrazol-1-yl)-benzoylamino]-butyric acid 
• 1415481-75-2 5'-[(1R,2R)-2-carboxy-1-(2-chlorobenzyl)-2-hydroxy-ethylcarbamoyl]-2',3'-difluoro-biphenyl-2-carboxylic acid 
• 1415481-69-4 2-{3-[(1R,2R)-2-carboxy-1-(2-chloro-benzyl)-2-hydroxy-ethylcarbamoyl]-propyl}-benzoic acid 
• 1415481-71-8 2-{3-[(1R,2R)-1-(2-chlorobenzyl)-2-ethoxycarbonyl-2-hydroxy-ethylcarbamoyl]-propyl}-benzoic acid 
• 1415481-70-7 2-{3-[(1R,2R)-2-butoxycarbonyl-1-(2-chloro-benzyl)-2-hydroxy-ethylcarbamoyl]-propyl}-benzoic acid 
• 1415481-68-3 (2R,3R)-3-amino-4-(2-chloro-phenyl)-2-hydroxy-butyric acid butyl ester hydrochloride 

Relevant academic research and scientific papers

NEPRILYSIN INHIBITORS

In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, a, R4, R5, and R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

NEPRILYSIN INHIBITORS

In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, X, R4, R5, and R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

NEPRILYSIN INHIBITORS

In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, R4, and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.